PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.
Michelle Shahbol, PharmD
Advertisement
Articles by Michelle Shahbol, PharmD
As the industry focuses more on value-based care, predictive modeling allows pharmacies to shift their services from a one-size-fits-all approach to a personalized, high-touch strategy.
Advertisement
Latest Updated Articles
A Predictive Modeling Primer for Specialty PharmacyPublished: February 5th 2020 | Updated:
PARP Inhibitors: A Novel Approach to Treating Ovarian CancerPublished: March 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
3
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
4
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
5
